Semaglutide Linked to Reduced Smoking-Related Healthcare Encounters in 222,000+ T2D Patients
In a target trial emulation of 222,942 patients including 5,967 semaglutide users, semaglutide was associated with significantly fewer tobacco use disorder encounters, cessation medication prescriptions, and cessation counseling vs. seven other diabetes drugs — with effects appearing within 30 days.
Quick Facts
What This Study Found
Semaglutide was associated with significantly lower tobacco use disorder-related healthcare encounters (HR 0.68-0.88), cessation medication prescriptions, and cessation counseling compared to seven other diabetes drugs, with effects emerging within 30 days.
Key Numbers
Nationwide US EHR database; patients with comorbid T2DM and tobacco use disorder; semaglutide vs. other diabetes drugs.
How They Did This
Target trial emulation using nationwide US electronic health records. Compared 5,967 new semaglutide users vs. users of 7 other antidiabetes medications (222,942 total) among patients with comorbid T2D and TUD. Outcomes: TUD-related medical encounters, cessation medication prescriptions, and cessation counseling over 12 months. Cox proportional hazards and Kaplan-Meier analyses.
Why This Research Matters
Tobacco use kills over 8 million people annually, and existing cessation aids have limited effectiveness. If semaglutide reduces smoking behavior, it could provide a completely new pharmacological approach to tobacco addiction — particularly valuable since many smokers have comorbid diabetes and obesity, conditions semaglutide already treats.
The Bigger Picture
This study, alongside similar findings for alcohol use disorder and Alzheimer's, suggests semaglutide may broadly modulate brain reward and addiction circuits through GLP-1 receptor activation. The rapid onset (within 30 days) suggests a direct neurological effect rather than an indirect benefit of weight loss or metabolic improvement. If confirmed in RCTs, GLP-1 agonists could become a multi-purpose treatment addressing addiction, metabolic disease, and neurodegeneration simultaneously.
What This Study Doesn't Tell Us
Observational study — cannot prove causation. Key limitation: lower TUD-related encounters could reflect reduced care-seeking rather than reduced smoking. No data on actual cigarette consumption or smoking status. Semaglutide users may differ systematically from comparator groups. Only T2D patients with documented TUD studied. Medication adherence not verified.
Questions This Raises
- ?Do semaglutide users actually smoke less, or do they just have fewer smoking-related medical encounters?
- ?Would semaglutide be effective as a smoking cessation aid in non-diabetic smokers?
- ?Is the rapid 30-day onset of effect consistent with direct GLP-1 receptor modulation of reward circuits?
Trust & Context
- Key Stat:
- Effects within 30 days semaglutide's association with reduced TUD-related encounters appeared within the first month of treatment — faster than expected from metabolic improvements, suggesting direct neurological effects
- Evidence Grade:
- Moderate — large target trial emulation with consistent results across comparator groups. However, observational design and reliance on healthcare encounter data rather than direct smoking measurement limit conclusions.
- Study Age:
- Published in 2024 in Annals of Internal Medicine, among the first systematic examinations of semaglutide's association with tobacco use disorder.
- Original Title:
- Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.
- Published In:
- Annals of internal medicine, 177(8), 1016-1027 (2024)
- Authors:
- Wang, William(3), Volkow, Nora D(3), Berger, Nathan A(2), Davis, Pamela B, Kaelber, David C, Xu, Rong
- Database ID:
- RPEP-09492
Evidence Hierarchy
Frequently Asked Questions
Could semaglutide help people quit smoking?
This study found that T2D patients starting semaglutide had fewer smoking-related medical visits, fewer smoking cessation prescriptions, and fewer counseling visits compared to patients starting other diabetes drugs — and the differences appeared within just 30 days. This suggests semaglutide may reduce the desire to smoke, but the study couldn't measure actual smoking behavior. Clinical trials specifically testing semaglutide for smoking cessation are needed.
Why would a diabetes drug affect smoking?
Nicotine addiction involves reward circuits in the brain that use the same neurotransmitter pathways (especially dopamine) that GLP-1 receptors help regulate. Semaglutide may reduce the rewarding effects of nicotine by activating GLP-1 receptors in these brain circuits, making smoking feel less satisfying. The fact that effects appeared within 30 days supports this brain-based mechanism rather than an indirect effect through weight or metabolic changes.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09492APA
Wang, William; Volkow, Nora D; Berger, Nathan A; Davis, Pamela B; Kaelber, David C; Xu, Rong. (2024). Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.. Annals of internal medicine, 177(8), 1016-1027. https://doi.org/10.7326/M23-2718
MLA
Wang, William, et al. "Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.." Annals of internal medicine, 2024. https://doi.org/10.7326/M23-2718
RethinkPeptides
RethinkPeptides Research Database. "Association of Semaglutide With Tobacco Use Disorder in Pati..." RPEP-09492. Retrieved from https://rethinkpeptides.com/research/wang-2024-association-of-semaglutide-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.